Search results
Order by most recent / most popular / relevance
Results: 1-5 of 5
Learned intermediary doctrine: Eleventh Circuit upholds summary judgment in favor of manufacturer in lawsuit claiming antidepressant caused suicide
- Edwards Wildman Palmer LLP
- -
- USA
- -
- May 28 2010
The 11th Circuit Court of Appeals recently relied upon the learned intermediary doctrine in affirming summary judgment in favor of Smithkline Beecham Corp. (“SBC”) in a lawsuit claiming that the antidepressant Paxil caused the decedent to commit suicide
Jury awards $141 million against Pfizer in connection with off-label use of Neurontin
- Edwards Wildman Palmer LLP
- -
- USA
- -
- April 7 2010
A federal jury in Boston recently returned a verdict against Pfizer Inc. in connection with claims that Pfizer unlawfully promoted off-label uses of its anti-epilepsy drug Neurontin
Botox maker files First Amendment suit against the FDA
- Edwards Wildman Palmer LLP
- -
- USA
- -
- November 3 2009
Allergan, Inc., the maker of the drug Botox, recently filed suit against the Food & Drug Administration, alleging that certain FDA regulations unconstitutionally restrict Allergan’s truthful speech regarding off-label uses of its drug
Jury finds in favor of botox manufacturer in off-label use trial
- Edwards Wildman Palmer LLP
- -
- USA
- -
- May 28 2010
A California jury recently returned a verdict in favor of Allergan, Inc., in a trial involving claims that Allergan’s promotion of an off-label use of its drug Botox caused the death of a pediatric patient suffering from cerebral palsy
Eight Circuit rejects FDA preemption defense raised by generic drug manufacturers
- Edwards Wildman Palmer LLP
- -
- USA
- -
- February 10 2010
On November 27, 2009, the United States Court of Appeals for the Eighth Circuit held that failure to warn claims directed at generic pharmaceutical manufacturers are not preempted by federal law
